NL190472C - Therapeutische preparaten met verlengde werking op basis van hydroxypropylmethylcellulose. - Google Patents

Therapeutische preparaten met verlengde werking op basis van hydroxypropylmethylcellulose.

Info

Publication number
NL190472C
NL190472C NLAANVRAGE8204893,A NL8204893A NL190472C NL 190472 C NL190472 C NL 190472C NL 8204893 A NL8204893 A NL 8204893A NL 190472 C NL190472 C NL 190472C
Authority
NL
Netherlands
Prior art keywords
hydroxypropylmethylcellulose
preparations based
therapeutic preparations
prolonged therapeutic
prolonged
Prior art date
Application number
NLAANVRAGE8204893,A
Other languages
English (en)
Dutch (nl)
Other versions
NL8204893A (nl
NL190472B (nl
Original Assignee
Forest Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories filed Critical Forest Laboratories
Publication of NL8204893A publication Critical patent/NL8204893A/nl
Publication of NL190472B publication Critical patent/NL190472B/xx
Application granted granted Critical
Publication of NL190472C publication Critical patent/NL190472C/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NLAANVRAGE8204893,A 1981-12-18 1982-12-17 Therapeutische preparaten met verlengde werking op basis van hydroxypropylmethylcellulose. NL190472C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/332,348 US4369172A (en) 1981-12-18 1981-12-18 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US33234881 1981-12-18

Publications (3)

Publication Number Publication Date
NL8204893A NL8204893A (nl) 1983-07-18
NL190472B NL190472B (nl) 1993-10-18
NL190472C true NL190472C (nl) 1994-03-16

Family

ID=23297834

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE8204893,A NL190472C (nl) 1981-12-18 1982-12-17 Therapeutische preparaten met verlengde werking op basis van hydroxypropylmethylcellulose.

Country Status (17)

Country Link
US (1) US4369172A (fr)
JP (1) JPS58110513A (fr)
AR (1) AR228699A1 (fr)
BE (1) BE895391A (fr)
CA (1) CA1195929A (fr)
CH (1) CH641670A5 (fr)
DE (1) DE3246492C2 (fr)
DK (1) DK160076C (fr)
ES (1) ES518321A0 (fr)
FR (1) FR2518409B1 (fr)
GB (1) GB2111386A (fr)
IL (1) IL67497A (fr)
IT (1) IT1164472B (fr)
MX (1) MX160316A (fr)
NL (1) NL190472C (fr)
SE (1) SE453796B (fr)
ZA (1) ZA829267B (fr)

Families Citing this family (341)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
US4591500A (en) * 1983-04-25 1986-05-27 Microencapsulation S.A. Tablet having the shape of a capsule, process and device for its preparation
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPH0662404B2 (ja) * 1983-06-14 1994-08-17 シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド 制御放出性ナプロキセンおよびナプロキセンナトリウム錠
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
FR2556965B1 (fr) * 1983-12-21 1986-08-22 Rhone Poulenc Sante Nouvelle forme galenique du ketoprofene a liberation controlee
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4695464A (en) * 1984-10-09 1987-09-22 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
AU592065B2 (en) * 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
HU195729B (en) * 1985-02-05 1988-07-28 Sandoz Ag Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
AT388101B (de) * 1985-02-05 1989-05-10 Sandoz Ag Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstofffreisetzung
AU598751B2 (en) * 1985-02-07 1990-07-05 Novartis Ag Pharmaceutical formulations with controlled release of the active substance
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
WO1987000044A1 (fr) * 1985-07-02 1987-01-15 The Upjohn Company Formulations therapeutiques presentant des caracteristiques de liberation bimodales
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
NL194822C (nl) * 1985-10-01 2003-04-03 Novartis Ag Preparaat voor orale toediening met geregelde afgifte en werkwijze voor de bereiding ervan.
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
IT1187750B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
JPS62286925A (ja) * 1986-06-06 1987-12-12 Terumo Corp 水酸化アルミニウムゲルを含有する外用薬組成物
EP0249347B1 (fr) * 1986-06-10 1994-06-29 Euroceltique S.A. Composition à libération contrôlée de dihydrocodéine
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
JPS6310702A (ja) * 1986-07-01 1988-01-18 Ube Ind Ltd 徐放化製剤の製造方法
US4861590A (en) * 1986-09-25 1989-08-29 Colgate-Palmolive Company Sustained release fluoride and calcium composition
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
DE3639073A1 (de) * 1986-11-14 1988-05-26 Klinge Co Chem Pharm Fab Feste arzneizubereitungen und verfahren zu ihrer herstellung
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4822629A (en) * 1986-12-12 1989-04-18 Norwich Eaton Pharmaceuticals, Inc. Azumolene dosage form
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4915952A (en) * 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US5023076A (en) * 1987-02-27 1991-06-11 Alza Corporation Lamina comprising carboxyvinyl polymer
EP0281200B1 (fr) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Composition pharmaceutique, granulé pharmaceutique et leur procédé de fabrication
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5500228A (en) * 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
EP0297866A3 (fr) * 1987-07-01 1989-12-13 The Boots Company PLC Agents thérapeutiques
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US4871731A (en) * 1987-10-07 1989-10-03 Marion Laboratories, Inc. Captopril and diltiazem composition and the like
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
GB8802391D0 (en) * 1988-02-03 1988-03-02 Ddsa Pharmaceuticals Ltd Medicinal formulations
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
GB8913889D0 (en) * 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
EP0489096B1 (fr) * 1989-08-25 1995-11-15 BIOGLAN IRELAND (R & D) LIMITED Preparations pharmaceutiques et appareil en permettant l'administration
US5130140A (en) * 1989-09-14 1992-07-14 Hoeschst-Roussel Pharmaceuticals Inc. Method of making direct dry compressible acetaminophen composition
US5037658A (en) * 1989-09-14 1991-08-06 Hoechst-Roussel Pharmaceuticals, Inc. Direct dry compressible acetaminophen composition
US5198228A (en) * 1989-09-14 1993-03-30 Hoechst-Roussel Pharmaceuticals Inc. Direct dry compressible acetaminophen tablet
US5476668A (en) * 1990-08-24 1995-12-19 Shin-Etsu Chemical Co., Ltd. Base for film-coating pharmaceuticals and method for preparing same
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5223248A (en) * 1991-02-11 1993-06-29 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing antiplaque properties
US5770588A (en) * 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
CA2067975C (fr) * 1991-05-20 2003-01-14 Cynthia M. Blase Comprime d'aspirine a matrice tamponnee
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
NL9102142A (nl) 1991-12-20 1993-07-16 Dagra Pharma Bv Zetpillen met vertraagde afgifte en werkwijze voor de bereiding daarvan.
EP0550108B1 (fr) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Composition thyroactive à libération contrÔlée
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
JP3007687B2 (ja) * 1992-09-10 2000-02-07 チルドレンズ メディカル センター コーポレイション 局所麻酔剤の持続性送達のための生分解性ポリマーマトリックス
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
CN1071570C (zh) * 1993-06-14 2001-09-26 詹森药业有限公司 阿司咪唑和假麻黄碱的缓释薄膜包衣片
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
WO1995011024A1 (fr) * 1993-10-19 1995-04-27 The Procter & Gamble Company Forme galenique picosulfate
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
HUT71408A (en) * 1994-01-14 1995-11-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
US5419917A (en) † 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5728402A (en) * 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
AU706541B2 (en) * 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US5614207A (en) * 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
WO1997004752A1 (fr) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Compositions pharmaceutiques d'oestrogenes conjugues et leurs modes d'emploi
US5955105A (en) * 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US20060068000A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
EP0954301A4 (fr) 1996-06-24 2006-03-08 Euro Celtique Sa Methodes sures d'anesthesie locale
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
US6004932A (en) * 1997-03-06 1999-12-21 Iowa State University Research Foundation, Inc. Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
CA2216215A1 (fr) * 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
US6010718A (en) 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
WO1999001114A1 (fr) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Anesthesie a effet prolonge injectee dans les interlignes articulaires et corporelles
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
IN186245B (fr) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
ID26082A (id) 1998-03-19 2000-11-23 Briston Myers Squib Company Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
JP2002531491A (ja) 1998-12-11 2002-09-24 ノストラム・ファーマスーティカルズ・インコーポレイテッド ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020025341A1 (en) * 1998-12-18 2002-02-28 Yihong Qiu Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6150410A (en) * 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
AU763464B2 (en) 1999-03-08 2003-07-24 Medicure Inc. Pyridoxal analogues for vitamin B-6 disorders
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
EP1210079A2 (fr) * 1999-08-20 2002-06-05 Ferrosan A/S Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif
EP1210117A2 (fr) * 1999-08-24 2002-06-05 Medicure International Inc. Traitement des pathologies cardio-vasculaires et connexes
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US20050037073A1 (en) * 2000-01-13 2005-02-17 Alpharx Inc. Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
ATE293119T1 (de) 2000-02-29 2005-04-15 Medicure Int Inc Cardioprotektive phosphonate
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
WO2002004421A2 (fr) 2000-07-07 2002-01-17 Medicure International Inc. Analogues de pyridoxine et de pyridoxal utilises comme agents de therapie cardio-vasculaire
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
WO2002036077A2 (fr) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Preparation decongestionnante et antihistaminique a prise quotidienne unique
WO2002040034A1 (fr) * 2000-11-14 2002-05-23 Vital Health Sciences Pty Ltd. Complexes de derives de phosphate
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
WO2002051402A1 (fr) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
US20020103110A1 (en) * 2001-01-26 2002-08-01 Spitzer A. Robert System and method for rectal administration of medication for treatment of migraines
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
EP1365745A2 (fr) * 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisees, compositions d'hormone de thyroide et technique de preparation
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
JP4745608B2 (ja) * 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030171436A1 (en) * 2001-10-29 2003-09-11 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
DE60238276D1 (de) * 2001-12-13 2010-12-23 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US20050176782A1 (en) * 2002-02-26 2005-08-11 Easterling W. J. Medicament and method for treating vulodynia
US20030162769A1 (en) * 2002-02-26 2003-08-28 Easterling W. Jerry Composition and method for treating vulvodynia
MXPA04012198A (es) * 2002-06-07 2005-04-08 Ranbaxy Lab Ltd Formulacion de liberacion prolongada de divalproex sodio.
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
WO2004028507A1 (fr) * 2002-09-24 2004-04-08 Akzo Nobel N.V. Methode permettant d'apporter des ameliorations a des comprimes pharmaceutiques comprenant une matrice a base d'ether de cellulose
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004064831A1 (fr) * 2003-01-17 2004-08-05 Vital Health Sciences Pty Ltd Composes possedant des proprietes antiproliferatives
SE0302947D0 (sv) * 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20040265323A1 (en) * 2003-05-16 2004-12-30 Mccormick Beth A. Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US7476403B2 (en) * 2003-06-16 2009-01-13 Andrx Pharmaceuticals, Llc Oral extended-release composition
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258944B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004264939A1 (en) * 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
CA2535398C (fr) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
CA2535780A1 (fr) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Produit antibiotique, son utilisation et sa formulation
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
CA2554771A1 (fr) 2004-01-30 2005-08-18 Johns Hopkins University Composes precurseurs de nitroxyle et methodes d'utilisation
NZ549567A (en) 2004-03-03 2009-10-30 Vital Health Sciences Pty Ltd Formulations comprising a tocopheryl phosphate tertiary amine alkaloid complex
EP2803357B1 (fr) 2004-06-25 2020-11-18 The Johns-Hopkins University Inhibiteurs d'angiogenèse
EP1771158A4 (fr) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Comprimé pour distribution par impulsion
WO2006002549A1 (fr) * 2004-07-07 2006-01-12 Medicure International Inc. Polytherapies faisant intervenir des inhibiteurs d'agregation plaquettaire
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US20060068004A1 (en) * 2004-09-28 2006-03-30 Aum Nutrapharm Inc. Buccal delivery of sea cucumber tablets
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (fr) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Compositions pharmaceutiques à saveur masquée avec substances porogènes gastrosolubles
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
CA2585165A1 (fr) * 2004-10-28 2006-05-18 Medicure International Inc. Analogues de pyridoxine a double activite anti-plaquettes et anti-coagulantes
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP1853272A1 (fr) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions d'oestrogenes non conjugues et procedes destines a leur utilisation
US20090233881A1 (en) * 2005-03-03 2009-09-17 Vital Health Sciences Pty. Ltd Compounds having anti-cancer properties
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2006133506A1 (fr) * 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd Charge comprenant un ou plusieurs dérivés de di- et/ou monophosphate d’agent de transfert d’électrons ou des complexes de ceux-ci
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
EP2324886A1 (fr) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Nouveaux analogues deutériés de tadalafil
WO2007016338A2 (fr) * 2005-07-29 2007-02-08 Goverment Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
AU2006317440A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CA2631653A1 (fr) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd. Composes ayant des proprietes modulatrices de la cytokine
ES2317450T3 (es) 2006-01-11 2009-04-16 Teva Pharmaceutical Industries Ltd. Formulacion de liberacion controlada de acido valproico y sus derivados.
US20070160667A1 (en) * 2006-01-11 2007-07-12 Nava Shterman Controlled release formulation of divalproex sodium
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2653955C (fr) * 2006-06-01 2015-10-27 Schering Corporation Compositions pharmaceutiques pour la liberation prolongee de phenylephrine
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
WO2008032208A2 (fr) * 2006-09-11 2008-03-20 Aurobindo Pharma Limited Formulation à libération prolongée d'un agent antiépileptique
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
EP2120578B1 (fr) 2007-01-19 2014-11-19 Xcovery, INC. Composés inhibiteurs de kinase
WO2008102235A1 (fr) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Formulations d'alfuzosine à libération contrôlée
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US8697866B2 (en) 2008-06-19 2014-04-15 Xcovery Holding Company Llc Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
US8729097B2 (en) 2008-10-06 2014-05-20 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2461804A4 (fr) * 2009-08-04 2013-10-02 Haren Treasurer Usage amélioré avec l'hormone thyroïdienne
WO2011055385A1 (fr) 2009-11-03 2011-05-12 Lupin Limited Préparation de lacosamide à libération modifiée
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
JP6023062B2 (ja) 2010-10-08 2016-11-09 エックスカバリー ホールディング カンパニー エルエルシー 置換ピリダジンカルボキサミド化合物
SI2665477T1 (sl) 2011-01-20 2016-02-29 Bionevia Pharmaceuticals Inc. Modificirano sproščanje epalrestata ali njegovega derivata in metode za uporabo le-teh
WO2012122586A1 (fr) 2011-03-15 2012-09-20 Phosphagenics Limited Nouvelle composition
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2983702A2 (fr) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions et procédés s'appliquant à des vaccins personnalisés contre les néoplasies
CN105407926A (zh) * 2013-05-31 2016-03-16 久光制药株式会社 口腔贴剂
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CA2936748C (fr) 2014-10-31 2017-08-08 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (fr) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
EP3364955B1 (fr) 2015-10-09 2022-04-20 RB Health (US) LLC Formulation pharmaceutique
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
AU2017339417C1 (en) 2016-10-03 2022-06-02 Hangzhou Highlightll Pharmaceutical Co., Ltd. Novel Jak1 selective inhibitors and uses thereof
NZ754168A (en) 2016-12-21 2024-08-30 Avecho Biotechnology Ltd Process for phosphorylating a complex alcohol
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
EP3788147A1 (fr) 2018-05-04 2021-03-10 Tollys Ligands de tlr3 qui activent à la fois des cellules épithéliales et myéloïdes
WO2020072700A1 (fr) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Lignées d'allèles uniques d'alh
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020131586A2 (fr) 2018-12-17 2020-06-25 The Broad Institute, Inc. Méthodes d'identification de néo-antigènes
EP3996914A4 (fr) * 2019-07-11 2023-08-02 Stenco, LLC Matériau biodégradable
US20230203477A1 (en) 2020-05-26 2023-06-29 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
WO2022189861A1 (fr) 2021-03-08 2022-09-15 Tollys Conjugués d'hydrates de carbone de ligands tlr3 et leurs utilisations
CN117897156A (zh) 2021-08-10 2024-04-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
WO2023076733A1 (fr) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Bibliothèques de mini-protéomes artificiels d'acide nucléique sélectionnées biologiquement

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
BE587330A (fr) * 1959-04-13 1900-01-01
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
CA1018456A (en) * 1972-06-26 1977-10-04 Hans Lowey Prolonged release lozenges
US3839319A (en) * 1973-01-26 1974-10-01 Dow Chemical Co Hydroxypropyl methylcellulose ethers and method of preparation
JPS5163927A (en) * 1974-11-28 1976-06-02 Shinetsu Chemical Co Ketsugoseiryokonajozaihokaizaino seizohoho
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals

Also Published As

Publication number Publication date
NL8204893A (nl) 1983-07-18
DK160076C (da) 1991-06-24
IL67497A (en) 1986-02-28
NL190472B (nl) 1993-10-18
MX160316A (es) 1990-02-01
AR228699A1 (es) 1983-03-30
GB2111386A (en) 1983-07-06
US4369172A (en) 1983-01-18
DE3246492A1 (de) 1983-06-30
JPH059413B2 (fr) 1993-02-04
DK160076B (da) 1991-01-28
IT1164472B (it) 1987-04-08
FR2518409A1 (fr) 1983-06-24
JPS58110513A (ja) 1983-07-01
BE895391A (fr) 1983-04-15
ES8402155A1 (es) 1984-01-16
IL67497A0 (en) 1983-05-15
GB2111386B (fr)
ZA829267B (en) 1983-08-31
ES518321A0 (es) 1984-01-16
SE453796B (sv) 1988-03-07
CH641670A5 (fr) 1984-03-15
DK560782A (da) 1983-06-19
CA1195929A (fr) 1985-10-29
DE3246492C2 (de) 1985-12-19
SE8207167L (sv) 1983-06-19
FR2518409B1 (fr) 1986-02-21
SE8207167D0 (sv) 1982-12-15
IT8212690A0 (it) 1982-12-16

Similar Documents

Publication Publication Date Title
NL190472C (nl) Therapeutische preparaten met verlengde werking op basis van hydroxypropylmethylcellulose.
ATE34076T1 (de) Shampoo.
IT8222771A0 (it) Siringa.
IT8283434A0 (it) Asciugacapelli.
NO156596C (no) Tannpleiemiddel.
NO822209L (no) Tannpleiemiddel.
FI824277L (fi) B.thuringiensiskristallint protein i e. coli
ES273345Y (es) Zapato perfeccionado.
NO160156C (no) Svinghjul.
DE3873127D1 (de) Therapeutische praeparate.
ATE24396T1 (de) Zahnpflegemittel.
NO156636C (no) Kirurgisk hefteapparat.
DE3862374D1 (de) Schlauchpumpe.
NO161294C (no) Tannpleiemiddel.
IT8222525A0 (it) Disposizione di manopola odontoiatrica.
ES264837Y (es) Conjunto reten.
NO890453L (no) Artropodicide preparater.
DK152219C (da) Azopigmentpraeparater
NL189947C (nl) Farmaceutische preparaten op basis van propionibacterien.
IT1215690B (it) Complesso di collegamento.
DK213382A (da) Herbicide praeparater
NO156134C (no) Gulvsluk.
IT8219307A0 (it) Cilindro di trattamento.
IT1229015B (it) Tomografia.
DE3280048D1 (de) Herzschrittmacher.

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
A85 Still pending on 85-01-01
BC A request for examination has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20021217